Skip to main content
Journal cover image

Vaccine-mediated protection against Merbecovirus and Sarbecovirus challenge in mice.

Publication ,  Journal Article
Martinez, DR; Schäfer, A; Gavitt, TD; Mallory, ML; Lee, E; Catanzaro, NJ; Chen, H; Gully, K; Scobey, T; Korategere, P; Brown, A; Smith, L ...
Published in: Cell Rep
October 31, 2023

The emergence of three highly pathogenic human coronaviruses-severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003, Middle Eastern respiratory syndrome (MERS)-CoV in 2012, and SARS-CoV-2 in 2019-underlines the need to develop broadly active vaccines against the Merbecovirus and Sarbecovirus betacoronavirus subgenera. While SARS-CoV-2 vaccines protect against severe COVID-19, they do not protect against other sarbecoviruses or merbecoviruses. Here, we vaccinate mice with a trivalent sortase-conjugate nanoparticle (scNP) vaccine containing the SARS-CoV-2, RsSHC014, and MERS-CoV receptor-binding domains (RBDs), which elicited live-virus neutralizing antibody responses. The trivalent RBD scNP elicited serum neutralizing antibodies against bat zoonotic Wuhan Institute of Virology-1 (WIV-1)-CoV, SARS-CoV, SARS-CoV-2 BA.1, SARS-CoV-2 XBB.1.5, and MERS-CoV live viruses. The monovalent SARS-CoV-2 RBD scNP vaccine only protected against Sarbecovirus challenge, whereas the trivalent RBD scNP vaccine protected against both Merbecovirus and Sarbecovirus challenge in highly pathogenic and lethal mouse models. This study demonstrates proof of concept for a single pan-sarbecovirus/pan-merbecovirus vaccine that protects against three highly pathogenic human coronaviruses spanning two betacoronavirus subgenera.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cell Rep

DOI

EISSN

2211-1247

Publication Date

October 31, 2023

Volume

42

Issue

10

Start / End Page

113248

Location

United States

Related Subject Headings

  • Severe acute respiratory syndrome-related coronavirus
  • SARS-CoV-2
  • Middle East Respiratory Syndrome Coronavirus
  • Mice
  • Humans
  • COVID-19 Vaccines
  • Antibodies, Viral
  • Antibodies, Neutralizing
  • Animals
  • 31 Biological sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Martinez, D. R., Schäfer, A., Gavitt, T. D., Mallory, M. L., Lee, E., Catanzaro, N. J., … Saunders, K. O. (2023). Vaccine-mediated protection against Merbecovirus and Sarbecovirus challenge in mice. Cell Rep, 42(10), 113248. https://doi.org/10.1016/j.celrep.2023.113248
Martinez, David R., Alexandra Schäfer, Tyler D. Gavitt, Michael L. Mallory, Esther Lee, Nicholas J. Catanzaro, Haiyan Chen, et al. “Vaccine-mediated protection against Merbecovirus and Sarbecovirus challenge in mice.Cell Rep 42, no. 10 (October 31, 2023): 113248. https://doi.org/10.1016/j.celrep.2023.113248.
Martinez DR, Schäfer A, Gavitt TD, Mallory ML, Lee E, Catanzaro NJ, et al. Vaccine-mediated protection against Merbecovirus and Sarbecovirus challenge in mice. Cell Rep. 2023 Oct 31;42(10):113248.
Martinez, David R., et al. “Vaccine-mediated protection against Merbecovirus and Sarbecovirus challenge in mice.Cell Rep, vol. 42, no. 10, Oct. 2023, p. 113248. Pubmed, doi:10.1016/j.celrep.2023.113248.
Martinez DR, Schäfer A, Gavitt TD, Mallory ML, Lee E, Catanzaro NJ, Chen H, Gully K, Scobey T, Korategere P, Brown A, Smith L, Parks R, Barr M, Newman A, Bowman C, Powers JM, Soderblom EJ, Mansouri K, Edwards RJ, Baric RS, Haynes BF, Saunders KO. Vaccine-mediated protection against Merbecovirus and Sarbecovirus challenge in mice. Cell Rep. 2023 Oct 31;42(10):113248.
Journal cover image

Published In

Cell Rep

DOI

EISSN

2211-1247

Publication Date

October 31, 2023

Volume

42

Issue

10

Start / End Page

113248

Location

United States

Related Subject Headings

  • Severe acute respiratory syndrome-related coronavirus
  • SARS-CoV-2
  • Middle East Respiratory Syndrome Coronavirus
  • Mice
  • Humans
  • COVID-19 Vaccines
  • Antibodies, Viral
  • Antibodies, Neutralizing
  • Animals
  • 31 Biological sciences